A Randomized Phase II Trial to Assess the Predictive Value of Increased EGFR Copy Number by FISH in Patients With Advanced / Metastatic NSCLC Treated With Cetuximab and Carboplatin / Paclitaxel.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 02 Nov 2015
At a glance
- Drugs Carboplatin; Cetuximab; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb; Eli Lilly
- 30 Oct 2008 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 22 Oct 2008 New trial record.